Or an asset sale. They sell all the IP for the anti-colesterol asset.
Keep some to accelerate R&D/ regulatory for the TBI drug, pay rest out as a special dividend.
A special dividend is exactly as it sounds, usually when a company has a big surplus of cash all of a sudden.
And yes, the SP would go up also.
Let's see if NYR can successfully commercialise the anti-colesterol the next year or two.
Ann: NYR Secures Collaboration with Walter Reed and UNSW, page-61
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
